Lafleur (Dienogest, Estradiol Valerate)

Estradiol valerate provides estrogenic activity that stabilizes the endometrial lining, while dienogest acts as a progestogen to suppress the luteinizing hormone surge, preventing ovulation. The combination also thickens cervical mucus and induces endometrial changes that lower the chance of implantation.

The specific dosing regimen for Lafleur is determined by the prescribing healthcare professional based on the patient’s clinical needs and local guidelines. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Lafleur is contraindicated during pregnancy because it is intended to prevent conception. Women who become pregnant should discontinue use immediately. Safety during breastfeeding has not been fully established; clinicians usually advise against use while nursing unless the benefits outweigh potential risks.

To place an order, submit an enquiry on the Lafleur product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lafleur combines estradiol valerate with dienogest, offering a specific estrogen‑progestogen balance that may provide better control of endometriosis‑related pain compared with some other formulations. Efficacy for contraception is comparable across combined oral contraceptives, while side‑effect profiles can vary based on the progestogen component.

Lafleur tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Lafleur is taken orally, usually once daily at the same time each day, as directed by the prescriber. The tablets are swallowed whole with water and should be taken with or without food according to the healthcare provider’s guidance.

Serious risks include venous thromboembolism, stroke, myocardial infarction, severe hypertension, and rare severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like sudden chest pain, shortness of breath, severe headache, or swelling of the face or throat.

Lafleur is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, known or suspected breast cancer, severe liver disease, or those who are pregnant. It should also be avoided by smokers over the age of 35 and by individuals taking interacting medications that diminish its effectiveness.